Toronto, Ontario and Chicago, Illinois — November 4, 2025 — Leads & Copy —
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) will host a conference call on Thursday, November 13, 2025, at 8:00 am Eastern Time to discuss its results for the second fiscal quarter ended September 30, 2025. The company expects to file its financial statements and MD&A after markets close on November 12, 2025.
To participate, dial 877-545-0523 (toll-free) for Canadian and U.S. callers or +1 973-528-0016 for international callers, using access code 988000. A live webcast will be available on the Investors section of Medexus’s corporate website. A replay will be available until November 20, 2025, by dialing 877-481-4010 (Canada and U.S.) or +1 919-882-2331 (international) with Conference ID 53180. The webcast replay will be available until November 13, 2026.
Medexus is a specialty pharmaceutical company focused on innovative and rare disease treatment solutions in hematology, hematology-oncology, rheumatology, allergy, and dermatology. For more information, visit www.medexus.com.
Ken d’Entremont | CEO, Medexus Pharmaceuticals, Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals, Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Victoria Rutherford | Adelaide Capital, Tel: 480-625-5772 | Email: victoria@adcap.ca
Source: Medexus Pharmaceuticals
